Clinical trial
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic…
NCT00117104 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00117104 |
|---|---|
| Title | Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis |
| Official title | A Multicenter Study Evaluating Once Weekly Intravenous Administration of Aranesp® in Subjects With End Stage Renal Disease on Chronic Hemodialysis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | End Stage Renal Disease |
| Intervention type | Drug |
| Interventions | Aranesp® |
| First posted | Jul 4, 2005 |
| Last update posted | Oct 16, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: